About Us | Contact

Dr. Erik Gaensler

Diagnostic Radiology Eden Medical Center NPI1376598474
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$599,054.80
from 63 payments in the last 6 years

Total Cash or Cash Equivalent

$598,887.08
from 60 payments in the last 6 years

Total In-kind Items & Services

$167.72
from 3 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
12/14/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $1405.00 Details
Payment from Genentech, Inc.
Payment Record ID 835910499
12/02/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $937.50 Details
Payment from Genentech, Inc.
Payment Record ID 835910497
12/07/2021 General (Non-Research) Cash or cash equivalent Food and Beverage $14.92 Details
Payment from Biogen, Inc.
Payment Record ID 827765841
12/07/2021 General (Non-Research) Cash or cash equivalent Travel and Lodging $11.69 Details
Payment from Biogen, Inc.
Payment Record ID 827765839
12/07/2021 General (Non-Research) Cash or cash equivalent Travel and Lodging $134.37 Details
Payment from Biogen, Inc.
Payment Record ID 827765837
12/07/2021 General (Non-Research) Cash or cash equivalent Travel and Lodging $375.80 Details
Payment from Biogen, Inc.
Payment Record ID 827765835
12/07/2021 General (Non-Research) Cash or cash equivalent Travel and Lodging $473.30 Details
Payment from Biogen, Inc.
Payment Record ID 827765833
11/17/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $4752.00 Details
Payment from Biogen, Inc.
Payment Record ID 827765831
06/24/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $2640.00 Details
Payment from Biogen, Inc.
Payment Record ID 827765829
04/15/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $792.00 Details
Payment from Biogen, Inc.
Payment Record ID 827765827
01/13/2021 Research Cash or cash equivalent $134985.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT04437511
Payment Record ID 819443889
12/07/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $3168.00 Details
Payment from Biogen, Inc.
Payment Record ID 737259287
12/16/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $2640.00 Details
Payment from Biogen, Inc.
Payment Record ID 737259285
09/09/2020 Research Cash or cash equivalent $2470.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT04437511
Payment Record ID 728719029
01/23/2019 Research Cash or cash equivalent $150.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY
Clinical Trials Gov ID NCT02972658
Payment Record ID 654282451
01/23/2019 Research Cash or cash equivalent $600.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA
Clinical Trials Gov ID NCT02783573
Payment Record ID 654282303
01/23/2019 Research Cash or cash equivalent $750.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY
Clinical Trials Gov ID NCT02245737
Payment Record ID 654282301
11/14/2018 General (Non-Research) In-kind items and services Food and Beverage $35.70 Details
Payment from Bard Peripheral Vascular, Inc.
Payment Record ID 609233355
08/24/2018 Research Cash or cash equivalent $2550.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY
Clinical Trials Gov ID NCT02972658
Payment Record ID 585602123
01/25/2018 Research Cash or cash equivalent $70300.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA
Clinical Trials Gov ID NCT02783573
Payment Record ID 585602121
01/25/2018 Research Cash or cash equivalent $42525.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY
Clinical Trials Gov ID NCT02245737
Payment Record ID 585602119
03/22/2017 General (Non-Research) In-kind items and services Food and Beverage $110.89 Details
Payment from EKOS Corporation
Payment Record ID 510942071
06/08/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504154227
05/17/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $150.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504154223
05/17/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $100.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504154220
04/26/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $100.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504154215
02/24/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $850.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503587799
02/24/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $400.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503587793
01/19/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $100.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503587779
01/19/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $2700.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503584881
01/19/2017 Research Cash or cash equivalent $33650.00 Details
Payment from Eli Lilly and Company
Paymment Research Study EFFECT OF PASSIVE IMMUNIZATION ON THE PROGRESSION OF MILD ALZHEIMERS DISEASE - SOLANEZUMAB -LY2062430- VERSUS PLACEBO
Clinical Trials Gov ID NCT01900665
Payment Record ID 457096929
01/19/2017 Research Cash or cash equivalent $13650.00 Details
Payment from Eli Lilly and Company
Paymment Research Study CONTINUED EFFICACY AND SAFETY MONITORING OF SOLANEZUMAB, AN ANTI-AMYLOID ANTIBODY IN PATIENTS WITH ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT01127633
Payment Record ID 457096927
01/19/2017 Research Cash or cash equivalent $45350.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA
Clinical Trials Gov ID NCT02783573
Payment Record ID 457096925
01/19/2017 Research Cash or cash equivalent $62962.50 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY
Clinical Trials Gov ID NCT02245737
Payment Record ID 457096923
12/22/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $9475.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406487496
11/16/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406487494
10/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $200.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406487492
11/16/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $1925.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406487184
10/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406484884
12/22/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $100.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406484872
08/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3675.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406083374
09/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $500.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406082874
08/17/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $4800.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406082872
08/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406082870
09/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $2975.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406082868
08/17/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $1725.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406082866
06/24/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $4125.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405768076
04/07/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $800.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766452
05/02/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $600.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766450
06/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $500.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766448
04/07/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $4200.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766446
06/24/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $400.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766444
05/02/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3025.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766442
06/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3000.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766440
02/03/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3050.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405707010
01/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3450.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704910
02/19/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $2800.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704908
02/03/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $625.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405703696
01/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $4975.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405703694
02/19/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $400.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405703692
01/15/2016 Research Cash or cash equivalent $61200.00 Details
Payment from Eli Lilly and Company
Paymment Research Study EFFECT OF PASSIVE IMMUNIZATION ON THE PROGRESSION OF MILD ALZHEIMERS DISEASE - SOLANEZUMAB -LY2062430- VERSUS PLACEBO
Clinical Trials Gov ID NCT01900665
Payment Record ID 372519490
04/07/2016 Research Cash or cash equivalent $44475.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY
Clinical Trials Gov ID NCT02245737
Payment Record ID 372519484
11/07/2016 General (Non-Research) In-kind items and services Food and Beverage $21.13 Details
Payment from Bayer HealthCare Pharmaceuticals Inc.
Payment Record ID 372373740
;